SERD (Selective Estrogen Receptor Degrader)
Drugs Market
SERD (Selective Estrogen Receptor Degrader)
Drugs Market Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
SERD (Selective Estrogen Receptor Degrader) Drugs
Market Size and Growth
The global SERD (Selective Estrogen Receptor Degrader) Drugs market is projected to witness substantial growth in the coming years due to increasing prevalence of hormone receptor-positive breast cancer. The market size is estimated to reach $X billion by 2025, driven by rising demand for effective treatment options and advancements in medical research.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Amneal Pharmaceuticals Inc
◍ AstraZeneca, Plc.
◍ Dr. Reddy's Laboratories
◍ Eli Lilly and Company
◍ G1 Therapeutics, Inc.
◍ Glenmark Pharmaceuticals
◍ HBT Labs, Inc
◍ Hoffmann-La Roche AG
◍ InventisBio
◍ Novartis AG
◍ Radius Health
◍ Sanofi S.A.
◍ Teva Pharmaceutical Industries Ltd.
◍ Zenopharm LLC.
◍ Zentalis Pharmaceuticals
The SERD market is competitive with companies such as AstraZeneca, Eli Lilly, Novartis, and more. They develop and market SERD drugs for breast cancer treatment. These companies contribute to market growth through research, development, and commercialization efforts.
- AstraZeneca: $25.8 billion
- Eli Lilly: $22.3 billion - Novartis: $48.5 billion
Request Sample Report
Market Segmentation
By Application
First-Line Treatment
Second-Line Treatment
Request Sample Report
By Product
RAD1901
GDC-9545
AZD9833
SAR439859
Faslodex
Others
◍
◍
◍
◍
◍
◍
◍
◍
Market Growth
Request Sample Report
$ X Billion USD
THANK YOU Email : sales@reportprime.com USA : +1 507 500 7209 Website : https://www.reportprime.com/ Request Sample Report Contact US Our Clients